Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

LEVETIRACETAM IN SODIUM CHLORIDE

LEVETIRACETAM

Standard Dose
250MG/50ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LEVETIRACETAM IN SODIUM CHLORIDE is listed in Drugs@FDA under application 202543 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVETIRACETAM Form and strength INJECTABLE;INTRAVENOUS - 250MG/50ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HQ SPCLT PHARMA Submission history Latest submission status date: 2024-03-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview LEVETIRACETAM IN SODIUM CHLORIDE is listed in Drugs@FDA under application 202543 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVETIRACETAM Form and strength INJECTABLE;INTRAVENOUS - 250MG/50ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HQ SPCLT PHARMA Submission history Latest submission status date: 2024-03-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.